Diabetic Foot Ulcers Pipeline Insight, 2025: Comprehensive Clinical Trials and Therapies Analysis

Strategic Insights -

The global Diabetic Foot Ulcers (DFUs) pipeline has been growing rapidly, with numerous companies working on novel therapies to treat this debilitating condition. According to a recent report by DelveInsight, there are 20+ key companies developing 25+ DFUs treatment therapies, with a focus on advancing the pipeline products from the pre-clinical developmental phase to the marketed phase. The report provides a comprehensive analysis of the drug, including the mechanism of action, clinical studies, NDA approvals, and product development activities.

Key Takeaways:

  • Companies such as Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others are working on developing novel therapies for the treatment of Diabetic Foot Ulcers.
  • Emerging therapies such as TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, and Galnobax are expected to have a significant impact on the market.
  • In October 2025, Celularity Inc. reported positive results from its Phase 2 clinical trial of PDA-002, a first-in-class regenerative therapy designed for treating diabetic foot ulcers (DFUs) complicated by peripheral artery disease (PAD).
  • In July 2025, Eluciderm Inc. obtained FDA clearance for its Investigational New Drug (IND) application to initiate a Phase I/IIa open-label trial assessing the safety and effectiveness of ELU-42, a topical spray-on solution designed to promote healing in patients with diabetic foot ulcers (DFUs).
  • In January 2025, BioStem Technologies, Inc. launched the BR-AM-DFU clinical trial to assess the effectiveness of Vendaje compared to the current standard of care in treating non-healing diabetic foot ulcers.
  • In October 2024, a clinical study conducted by Kerecis showed that fish-skin grafts are more effective than standard treatments for closing various types of diabetic foot ulcers.
  • The Diabetic Foot Ulcers pipeline report provides insights into the commercial and clinical assessment of the pipeline products, including the mechanism of action, clinical studies, NDA approvals, and product development activities.

Statistics:

  • 20+ key companies are developing 25+ Diabetic Foot Ulcers treatment therapies.
  • 10+ emerging therapies are in the pipeline, including TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, and Galnobax.
  • 5+ clinical trials are ongoing, including the Phase 2 clinical trial of PDA-002 and the Phase I/IIa open-label trial of ELU-42.
  • The global prevalence of foot ulcers in diabetic patients is increasing, driving the growth of the Diabetic Foot Ulcers market.
  • The market is expected to grow due to the rise in research and development activities, technological advancements, and increasing demand for innovative therapies.

Sources:

  • DelveInsight's Diabetic Foot Ulcers Report, 2025.
  • M2 Communications.
  • DelveInsight's website: https://www.delveinsight.com/.